Cara Therapeutics Stock Price, News & Analysis (NASDAQ:CARA)

$13.87 +0.06 (+0.43 %)
(As of 02/22/2018 04:00 PM ET)
Previous Close$13.87
Today's Range$13.77 - $14.22
52-Week Range$11.11 - $28.50
Volume491,658 shs
Average Volume1.26 million shs
Market Capitalization$452.28 million
P/E Ratio-6.06
Dividend YieldN/A
Beta3.01

About Cara Therapeutics (NASDAQ:CARA)

Cara Therapeutics logoCara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.

Receive CARA News and Ratings via Email

Sign-up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CARA
CUSIPN/A
Phone+1-203-4063700

Debt

Debt-to-Equity RatioN/A
Current Ratio14.58%
Quick Ratio14.58%

Price-To-Earnings

Trailing P/E Ratio-6.05676855895196
Forward P/E Ratio-7.50
P/E GrowthN/A

Sales & Book Value

Annual Sales$90,000.00
Price / Sales5,025.56
Cash FlowN/A
Price / CashN/A
Book Value$1.86 per share
Price / Book7.46

Profitability

Trailing EPS($2.29)
Net Income$-57,280,000.00
Net MarginsN/A
Return on Equity-91.47%
Return on Assets-79.15%

Miscellaneous

Employees34
Outstanding Shares32,610,000

Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics Inc (NASDAQ:CARA) released its earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.03. During the same quarter last year, the business earned ($0.42) EPS. View Cara Therapeutics' Earnings History.

Where is Cara Therapeutics' stock going? Where will Cara Therapeutics' stock price be in 2018?

13 equities research analysts have issued 1 year target prices for Cara Therapeutics' shares. Their forecasts range from $17.00 to $31.50. On average, they expect Cara Therapeutics' stock price to reach $26.04 in the next year. View Analyst Ratings for Cara Therapeutics.

What are Wall Street analysts saying about Cara Therapeutics stock?

Here are some recent quotes from research analysts about Cara Therapeutics stock:

  • 1. According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (1/5/2018)
  • 2. Needham & Company LLC analysts commented, "Cara announced outcome of planned CR845 Phase 2/3 post-surgical pain trial interim power assessment today. We spoke w/ mgmt for an update. No changes will be made to current randomization ratio across the 3 arms (1:1:1 placebo, 0.5 ug/kg, 1.0ug/kg), however target enrollment will be increased from 125/ arm to 150/ arm. Other pre-specified options were ending trial early due to low probability of success or shifting enrollment to one optimal dose. We view outcome favorably, noting that the two dose arms were evaluated independently by Data Monitoring Cmtee. Implication is that both low and high dose CR845 have potential for statistically significant effect in view of DMC. We had been concerned that low and possibly high dose evaluated in this trial may not be sufficiently high for efficacy. Mgmt guided for completing enrollment for final analysis by YE17. Separately, top-line results from CR845 Phase 2b trial in Osteoarthritis are expected later this month. We are favorably inclined based on encouraging trends in an 80-pt 2wk Phase 2a trial, but acknowledge risks tied to absence of placebo arm." (6/21/2017)
  • 3. HC Wainwright analysts commented, "CR845 as safe as placebo in respiratory safety Phase 1. Cara announced positive data this morning from a 15-patient Phase 1 trial in healthy volunteers designed to formally test for IV ‘845’s impact on respiratory drive, as respiratory depression remains one of the more severe, and potentially life-threatening, side effects of mu opioids, which ‘845 is not. The trial was a three-way crossover design utilizing the expected therapeutic dose of 1.0 ug/kg, as well as a 5.0 ug/kg supratherapeutic dose to test the upper bounds for safety. Patient respiratory drive was measured via end-tidal CO2 (ETCO2), oxygen saturation (SpO2), and respiratory rate, with primary endpoints focused on the former two. ETCO2 ranged from 36.1 to 37.8 mmHg prior to dosing, and remained well below the endpoint threshold of a 10mmHg sustained increase in ETCO2, with values of 38.1, 38.1, and 38.3 mmHg for the placebo, 1.0 ug/kg, and 5.0 ug/kg doses, respectively, one hour after administration. Both doses of ‘845 also hit on the SpO2 primary endpoint (needed to show SpO2 which did not consistently fall below 92%), with pre-treatment levels ranging from 98.3% to 98.9%, finishing an hour later at 97.8%, 98.2%, and 97.9% for the placebo,1.0 ug/kg, and 5.0 ug/kg doses, respectively. While these two primary endpoints only measured through an hour after treatment, no significant differences were seen on all three measures of respiratory drive throughout the entire 4-hour observation period of the study." (4/24/2017)
  • 4. Cantor Fitzgerald analysts commented, "The Phase 1 safety trial of IV CR845 showed no significant differences in respiratory drive vs. placebo at super-therapeutic dosing levels." (4/24/2017)
  • 5. Piper Jaffray Companies analysts commented, "Today Cara reported positive results from Part A of its Phase II/III trial for IV CR845 in uremic pruritus (UP). In our view, these results are compelling in terms of impact on worst itching scores together with more global measures of quality of life within the context of an 8-week study, as well as safety/tolerability at the go-forward doses of 0.5mcg/kg and 1.0mcg/kg. We see the robust efficacy vs safety data from this Phase II as reducing clinical risk for a broader pivotal program planned to begin by YE17. And beyond the Phase III program, we see this dataset as potentially reducing regulatory and commercial risk, and enhancing value of this asset, in the longer-term. In advance of further clinical progress in UP, including an EOP2 and Phase III start yet in '17, as well as chronic pain and post-op pain updates during 2Q17, we reiterate OW on Cara." (3/28/2017)

Who are some of Cara Therapeutics' key competitors?

Who are Cara Therapeutics' key executives?

Cara Therapeutics' management team includes the folowing people:

  • Derek T. Chalmers Ph.D., President, Chief Executive Officer, Director (Age 53)
  • Mani Mohindru Ph.D., Chief Financial Officer, Chief Strategy Officer (Age 45)
  • Michael E. Lewis, Chief Scientific Officer (Age 65)
  • Frederique Menzaghi Ph.D, Vice President, Research & Development (Age 50)
  • Joseph William Stauffer, Chief Medical Officer (Age 50)
  • Harrison M. Bains Jr., Independent Director (Age 73)
  • Jeffrey L. Ives Ph.D., Independent Director (Age 66)
  • Dean Slagel, Independent Director (Age 47)
  • Martin A. Vogelbaum, Independent Director (Age 53)

Who owns Cara Therapeutics stock?

Cara Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.77%), Disciplined Growth Investors Inc. MN (2.64%), Franklin Resources Inc. (1.38%), C WorldWide Group Holding A S (0.82%), California Public Employees Retirement System (0.44%) and First Manhattan Co. (0.31%). Company insiders that own Cara Therapeutics stock include Dean Slagel, Derek T Chalmers, Frederique PhD Menzaghi and Ventures Vi Lp Rho. View Institutional Ownership Trends for Cara Therapeutics.

Who sold Cara Therapeutics stock? Who is selling Cara Therapeutics stock?

Cara Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including TIAA CREF Investment Management LLC, Deutsche Bank AG, C WorldWide Group Holding A S, California Public Employees Retirement System, Wells Fargo & Company MN, Metropolitan Life Insurance Co. NY, Meadow Creek Investment Management LLC and Rhumbline Advisers. Company insiders that have sold Cara Therapeutics company stock in the last year include Dean Slagel, Derek T Chalmers and Frederique PhD Menzaghi. View Insider Buying and Selling for Cara Therapeutics.

Who bought Cara Therapeutics stock? Who is buying Cara Therapeutics stock?

Cara Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., First Manhattan Co., Goldman Sachs Group Inc., Virtus Fund Advisers LLC, LPL Financial LLC, Raymond James & Associates, Franklin Resources Inc. and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Cara Therapeutics.

How do I buy Cara Therapeutics stock?

Shares of Cara Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cara Therapeutics' stock price today?

One share of Cara Therapeutics stock can currently be purchased for approximately $13.87.

How big of a company is Cara Therapeutics?

Cara Therapeutics has a market capitalization of $452.28 million and generates $90,000.00 in revenue each year. The biopharmaceutical company earns $-57,280,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis. Cara Therapeutics employs 34 workers across the globe.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 4 Stamford Plz, STAMFORD, CT 06902-3834, United States. The biopharmaceutical company can be reached via phone at +1-203-4063700.


MarketBeat Community Rating for Cara Therapeutics (CARA)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  409 (Vote Outperform)
Underperform Votes:  185 (Vote Underperform)
Total Votes:  594
MarketBeat's community ratings are surveys of what our community members think about Cara Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cara Therapeutics (NASDAQ:CARA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.852.772.752.82
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $26.04$26.04$26.19$26.67
Price Target Upside: 111.67% upside109.29% upside116.47% upside63.20% upside

Cara Therapeutics (NASDAQ:CARA) Consensus Price Target History

Price Target History for Cara Therapeutics (NASDAQ:CARA)

Cara Therapeutics (NASDAQ:CARA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2018Janney Montgomery ScottUpgradeNeutral -> Buy$27.00 -> $21.00HighView Rating Details
1/19/2018Seaport Global SecuritiesInitiated CoverageBuy -> Buy$27.00MediumView Rating Details
1/3/2018Stifel NicolausReiterated RatingBuy$17.00HighView Rating Details
11/20/2017Canaccord GenuitySet Price TargetBuy$25.00N/AView Rating Details
11/7/2017Raymond James FinancialBoost Price TargetMarket Perform$25.00 -> $26.00N/AView Rating Details
11/7/2017CIBCLower Price Target$26.00 -> $24.00N/AView Rating Details
11/7/2017BMO Capital MarketsReiterated RatingMarket Perform$25.00N/AView Rating Details
10/17/2017ScotiabankBoost Price TargetOutperform$31.00 -> $31.50N/AView Rating Details
10/4/2017Needham & Company LLCReiterated RatingBuy$23.00LowView Rating Details
8/5/2017Piper Jaffray CompaniesSet Price TargetBuy$27.00HighView Rating Details
8/4/2017HC WainwrightReiterated RatingBuy$30.00HighView Rating Details
8/3/2017Royal Bank of CanadaLower Price TargetOutperform$31.00 -> $29.00LowView Rating Details
6/30/2017LaidlawLower Price TargetBuy$35.00 -> $30.00HighView Rating Details
5/19/2017Cantor FitzgeraldReiterated RatingOverweight$29.00LowView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Cara Therapeutics (NASDAQ:CARA) Earnings History and Estimates Chart

Earnings by Quarter for Cara Therapeutics (NASDAQ:CARA)

Cara Therapeutics (NASDAQ CARA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($0.35)($0.38)$0.27 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.61)($0.29)$0.13 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.73)($0.81)$0.11 million$0.91 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.53)($0.81)ViewN/AView Earnings Details
11/3/2016Q3($0.47)($0.42)$0.09 millionViewN/AView Earnings Details
8/4/2016Q216($0.42)($0.48)$0.13 million$0.08 millionViewN/AView Earnings Details
5/5/2016Q116($0.40)($0.39)$0.03 million$0.01 millionViewN/AView Earnings Details
3/10/2016Q4($0.33)($0.35)$0.53 millionViewListenView Earnings Details
11/9/2015Q315($0.27)($0.19)$1.86 million$2.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.24)($0.25)$0.50 million$0.87 millionViewListenView Earnings Details
5/12/2015Q415($0.22)($0.21)$0.70 million$0.50 millionViewListenView Earnings Details
3/26/2015Q4($0.28)($0.18)$1.00 million$0.91 millionViewListenView Earnings Details
11/10/2014Q314($0.22)($0.29)$0.13 million$1.13 millionViewN/AView Earnings Details
8/7/2014Q2($0.27)($0.16)$0.08 million$0.96 millionViewN/AView Earnings Details
5/12/2014Q1($0.14)($0.22)$0.30 million$0.18 millionViewN/AView Earnings Details
3/27/2014($0.18)($0.49)$0.90 million$0.97 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Cara Therapeutics (NASDAQ:CARA) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.85 EPS
Next Year EPS Consensus Estimate: $-1.87 EPS

Dividends

Dividend History for Cara Therapeutics (NASDAQ:CARA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cara Therapeutics (NASDAQ CARA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.70%
Institutional Ownership Percentage: 58.86%
Insider Trades by Quarter for Cara Therapeutics (NASDAQ:CARA)
Institutional Ownership by Quarter for Cara Therapeutics (NASDAQ:CARA)

Cara Therapeutics (NASDAQ CARA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/16/2018Derek T ChalmersCEOSell5,400$15.00$81,000.001,071,392View SEC Filing  
2/15/2018Frederique Ph.D. MenzaghiSVPSell3,000$15.02$45,060.00119,000View SEC Filing  
1/24/2018Derek T ChalmersCEOSell12,500$15.00$187,500.001,073,792View SEC Filing  
1/24/2018Frederique Ph.D. MenzaghiSVPSell15,000$15.00$225,000.00122,000View SEC Filing  
11/1/2017Derek T ChalmersCEOSell16,000$12.66$202,560.001,066,292View SEC Filing  
7/14/2017Derek T ChalmersCEOSell25,000$15.05$376,250.001,107,292View SEC Filing  
7/14/2017Frederique Ph.D. MenzaghiVPSell3,000$15.00$45,000.00120,000View SEC Filing  
6/29/2017Dean SlagelDirectorSell250,000$25.87$6,467,500.00View SEC Filing  
3/31/2017Ventures Vi Lp RhoMajor ShareholderBuy500,000$18.19$9,095,000.00View SEC Filing  
4/20/2016Frederique Ph.D. MenzaghiVPSell6,000$9.00$54,000.00123,000View SEC Filing  
3/17/2016Ventures Vi Lp RhoMajor ShareholderBuy400,000$4.87$1,948,000.00View SEC Filing  
2/3/2016Frederique Ph.D. MenzaghiVPSell6,000$9.04$54,240.00129,000View SEC Filing  
1/26/2016Michael E LewisInsiderSell7,262$10.93$79,373.66314,988View SEC Filing  
1/6/2016Derek T ChalmersCEOSell12,500$17.22$215,250.001,087,292View SEC Filing  
12/1/2015Frederique Ph.D. MenzaghiVPSell6,000$16.21$97,260.00141,000View SEC Filing  
11/2/2015Frederique Ph.D. MenzaghiVPSell6,000$14.26$85,560.00147,000View SEC Filing  
10/1/2015Frederique Ph.D. MenzaghiVPSell6,000$13.95$83,700.00153,000View SEC Filing  
9/1/2015Frederique Ph.D. MenzaghiVPSell7,000$18.63$130,410.00159,000View SEC Filing  
8/18/2015Josef SchoellCFOBuy3,000$22.10$66,300.0028,000View SEC Filing  
6/1/2015Michael E LewisInsiderSell7,262$9.50$68,989.00View SEC Filing  
5/19/2015Dean SlagelDirectorSell188,811$10.02$1,891,886.22View SEC Filing  
4/1/2015Michael E LewisInsiderSell7,262$9.90$71,893.80View SEC Filing  
3/2/2015Michael E LewisInsiderSell7,262$10.11$73,418.82View SEC Filing  
2/2/2015Michael E LewisInsiderSell7,262$10.60$76,977.20View SEC Filing  
2/5/2014Ventures Vi Lp RhoMajor ShareholderBuy225,818$11.00$2,483,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cara Therapeutics (NASDAQ CARA) News Headlines

Source:
DateHeadline
Cara Therapeutics Inc (CARA) CEO Sells $81,000.00 in StockCara Therapeutics Inc (CARA) CEO Sells $81,000.00 in Stock
www.americanbankingnews.com - February 21 at 6:46 PM
Cara Therapeutics Inc (CARA) SVP Frederique Ph.D. Menzaghi Sells 3,000 SharesCara Therapeutics Inc (CARA) SVP Frederique Ph.D. Menzaghi Sells 3,000 Shares
www.americanbankingnews.com - February 20 at 7:32 PM
Cara Therapeutics (CARA) & WuXi PharmaTech (Cayman) (WX) Financial ReviewCara Therapeutics (CARA) & WuXi PharmaTech (Cayman) (WX) Financial Review
www.americanbankingnews.com - February 19 at 3:16 PM
Cara Therapeutics (CARA) Upgraded to "Hold" at ValuEngineCara Therapeutics (CARA) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - February 13 at 10:48 PM
Focused on Two SectorsFocused on Two Sectors
finance.yahoo.com - February 13 at 3:07 PM
Marijuana stocks to consider for the long term - Motley FoolMarijuana stocks to consider for the long term - Motley Fool
www.fool.com - February 13 at 5:09 AM
Cara Therapeutics (CARA) Upgraded to Buy by Janney Montgomery ScottCara Therapeutics (CARA) Upgraded to Buy by Janney Montgomery Scott
www.americanbankingnews.com - February 12 at 9:34 PM
Forget Amgen -- Cara Therapeutics, Inc. Is a Better Growth Stock ... - Motley FoolForget Amgen -- Cara Therapeutics, Inc. Is a Better Growth Stock ... - Motley Fool
www.fool.com - February 9 at 3:11 PM
Cara Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference - GlobeNewswire (press release)Cara Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - February 8 at 8:01 AM
Cara Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceCara Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 8:01 AM
3 Marijuana Stock Buyout Candidates - Motley Fool3 Marijuana Stock Buyout Candidates - Motley Fool
www.fool.com - February 6 at 5:03 AM
Cara Therapeutics Inc (CARA) Receives Average Rating of "Buy" from AnalystsCara Therapeutics Inc (CARA) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - February 3 at 5:28 AM
Cara Therapeutics launches late-stage study of CR845 in CKD-aP - Seeking AlphaCara Therapeutics launches late-stage study of CR845 in CKD-aP - Seeking Alpha
seekingalpha.com - February 2 at 3:07 PM
Cara Therapeutics (CARA) Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA Injection in Hemodialysis Patients with CKD-aPCara Therapeutics (CARA) Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA Injection in Hemodialysis Patients with CKD-aP
www.streetinsider.com - February 2 at 5:03 AM
A Look at Cara Therapeutics’ Intravenous CR845A Look at Cara Therapeutics’ Intravenous CR845
finance.yahoo.com - February 2 at 5:03 AM
Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA™ (CR845/difelikefalin) Injection in ... - GlobeNewswire (press release)Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA™ (CR845/difelikefalin) Injection in ... - GlobeNewswire (press release)
globenewswire.com - February 1 at 3:01 PM
Look Beyond Pharma to Invest in Marijuana IndustryLook Beyond Pharma to Invest in Marijuana Industry
finance.yahoo.com - February 1 at 3:01 PM
Analysts’ Recommendations for Cara Therapeutics in January 2018Analysts’ Recommendations for Cara Therapeutics in January 2018
finance.yahoo.com - February 1 at 3:01 PM
Cara Therapeutics (CARA) Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA Injection in Hemodialysis Patients with ... - StreetInsider.comCara Therapeutics (CARA) Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA Injection in Hemodialysis Patients with ... - StreetInsider.com
www.streetinsider.com - February 1 at 5:10 AM
BRIEF-Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial Of Korsuva InjectionBRIEF-Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial Of Korsuva Injection
www.reuters.com - January 31 at 3:09 PM
Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA™ (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated PruritusCara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA™ (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus
finance.yahoo.com - January 31 at 3:09 PM
Reviewing WuXi PharmaTech (Cayman) (WX) and Cara Therapeutics (CARA)Reviewing WuXi PharmaTech (Cayman) (WX) and Cara Therapeutics (CARA)
www.americanbankingnews.com - January 30 at 11:06 AM
Stock Traders Purchase High Volume of Cara Therapeutics Call Options (CARA)Stock Traders Purchase High Volume of Cara Therapeutics Call Options (CARA)
www.americanbankingnews.com - January 28 at 1:26 AM
Derek T. Chalmers Sells 12,500 Shares of Cara Therapeutics Inc (CARA) StockDerek T. Chalmers Sells 12,500 Shares of Cara Therapeutics Inc (CARA) Stock
www.americanbankingnews.com - January 26 at 9:28 PM
Cara Therapeutics Inc (CARA) SVP Frederique Ph.D. Menzaghi Sells 15,000 SharesCara Therapeutics Inc (CARA) SVP Frederique Ph.D. Menzaghi Sells 15,000 Shares
www.americanbankingnews.com - January 26 at 9:28 PM
5 Biotechs That May Surge On Takeovers5 Biotechs That May Surge On Takeovers
finance.yahoo.com - January 26 at 3:01 PM
Cara Therapeutics Inc. (CARA) Has Broken Out To A 5-Month HighCara Therapeutics Inc. (CARA) Has Broken Out To A 5-Month High
www.nasdaq.com - January 26 at 5:09 AM
Could Cara Therapeutics, Inc. Be a Millionaire-Maker Stock?Could Cara Therapeutics, Inc. Be a Millionaire-Maker Stock?
finance.yahoo.com - January 26 at 5:09 AM
Why Cara Therapeutics Inc (NASDAQ:CARA) Has Zero-Debt On Its Balance SheetWhy Cara Therapeutics Inc (NASDAQ:CARA) Has Zero-Debt On Its Balance Sheet
finance.yahoo.com - January 26 at 5:09 AM
Cara Therapeutics breaks out, up 13% - Seeking AlphaCara Therapeutics breaks out, up 13% - Seeking Alpha
seekingalpha.com - January 24 at 3:14 PM
Could Cara Therapeutics, Inc. Be a Millionaire-Maker Stock? - Motley FoolCould Cara Therapeutics, Inc. Be a Millionaire-Maker Stock? - Motley Fool
www.fool.com - January 24 at 3:14 PM
The Top 3 Shareholders of Cara Therapeutics (CARA)The Top 3 Shareholders of Cara Therapeutics (CARA)
finance.yahoo.com - January 24 at 3:14 PM
Five biotech buyout candidates you should look at right nowFive biotech buyout candidates you should look at right now
finance.yahoo.com - January 24 at 7:07 AM
Cara Therapeutics (CARA) Now Covered by Seaport Global SecuritiesCara Therapeutics (CARA) Now Covered by Seaport Global Securities
www.americanbankingnews.com - January 20 at 3:28 PM
Legalization Boost Sales in Cannabis ProductsLegalization Boost Sales in Cannabis Products
www.prnewswire.com - January 12 at 9:46 AM
Cara Therapeutics Inc (CARA) Given Average Recommendation of "Buy" by BrokeragesCara Therapeutics Inc (CARA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 9 at 7:42 AM
The case for Cara Therapeutics - Motley FoolThe case for Cara Therapeutics - Motley Fool
www.fool.com - January 7 at 11:03 AM
Cara Therapeutics (CARA) Downgraded by Zacks Investment Research to "Sell"Cara Therapeutics (CARA) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - January 5 at 5:56 PM
Cara Therapeutics (CARA) Rating Reiterated by Stifel NicolausCara Therapeutics (CARA) Rating Reiterated by Stifel Nicolaus
www.americanbankingnews.com - January 3 at 8:20 AM
Is Cara Therapeutics, Inc. a Buy?Is Cara Therapeutics, Inc. a Buy?
finance.yahoo.com - December 18 at 10:00 AM
Cara Therapeutics Inc (CARA) Given Consensus Recommendation of "Buy" by AnalystsCara Therapeutics Inc (CARA) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 15 at 6:22 AM
Cramer's lightning round: Buy Wynn Resorts on a pullbackCramer's lightning round: Buy Wynn Resorts on a pullback
finance.yahoo.com - December 12 at 10:07 AM
Cramer's lightning round: Buy Wynn Resorts on a pullbackCramer's lightning round: Buy Wynn Resorts on a pullback
finance.yahoo.com - December 12 at 10:07 AM
Why 2018 Could Be the Best Year Yet for Cara Therapeutics - Motley FoolWhy 2018 Could Be the Best Year Yet for Cara Therapeutics - Motley Fool
www.fool.com - December 11 at 5:21 PM
Cara Therapeutics Target of Unusually Large Options Trading (CARA)Cara Therapeutics Target of Unusually Large Options Trading (CARA)
www.americanbankingnews.com - December 10 at 2:08 AM
Cara Therapeutics (CARA) Lowered to "Sell" at ValuEngineCara Therapeutics (CARA) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - December 3 at 8:44 PM
Cara Therapeutics (CARA) Upgraded at BidaskClubCara Therapeutics (CARA) Upgraded at BidaskClub
www.americanbankingnews.com - December 2 at 2:38 PM
Cara Therapeutics, Inc. (CARA) Given a $25.00 Price Target by Canaccord Genuity AnalystsCara Therapeutics, Inc. (CARA) Given a $25.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - November 21 at 8:14 PM
Cara Therapeutics, Inc. (CARA) Receives Average Recommendation of "Buy" from AnalystsCara Therapeutics, Inc. (CARA) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 20 at 6:04 AM
Cara Therapeutics (CARA) Presents At Jefferies 2017 London Healthcare Conference - SlideshowCara Therapeutics (CARA) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
seekingalpha.com - November 17 at 2:32 PM

SEC Filings

Cara Therapeutics (NASDAQ:CARA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cara Therapeutics (NASDAQ:CARA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cara Therapeutics (NASDAQ CARA) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.